Filing Details
- Accession Number:
- 0001610717-24-000511
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-18 18:25:19
- Reporting Period:
- 2024-10-17
- Accepted Time:
- 2024-10-18 18:25:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1885522 | Neumora Therapeutics Inc. | NMRA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1397266 | K Matthew Fust | C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-10-17 | 3,783 | $8.32 | 23,883 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 1,800 | $8.79 | 25,683 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 2,156 | $2.52 | 27,839 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-17 | 7,739 | $17.01 | 20,100 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-10-18 | 6,205 | $8.79 | 26,305 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-18 | 7,844 | $2.52 | 34,149 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-18 | 14,049 | $17.03 | 20,100 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-17 | 3,783 | $0.00 | 3,783 | $8.32 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-17 | 1,800 | $0.00 | 1,800 | $8.79 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-17 | 2,156 | $0.00 | 2,156 | $2.52 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-18 | 6,205 | $0.00 | 6,205 | $8.79 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-18 | 7,844 | $0.00 | 7,844 | $2.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2030-09-07 | No | 4 | M | Direct | |
| 6,205 | 2030-09-07 | No | 4 | M | Direct | |
| 93,430 | 2031-04-22 | No | 4 | M | Direct | |
| 0 | 2030-09-07 | No | 4 | M | Direct | |
| 85,586 | 2031-04-22 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024.
- This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
